Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Emerging Company Profile

Luminary: turning cell engineering tools into therapies

Former B-MoGen execs leverage experience in non-viral cell engineering tools to form therapeutic start-up

By Sandi Wong, Assistant Editor
August 22, 2020 2:16 AM UTC

Luminary is parlaying its founders’ experience in non-viral genome engineering to build a pipeline of cell therapies that are faster to develop and more cost-effective than those that depend on virus-based technologies.

Luminary Therapeutics Inc. was carved out of B-MoGen Biotechnologies Inc. in 2019 during B-MoGen’s acquisition by research tools and services company Bio-Techne Corp. (NASDAQ:TECH)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Luminary Therapeutics Inc.